AbbVie Inc. $ABBV Shares Sold by Sapient Capital LLC

Sapient Capital LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 219,951 shares of the company’s stock after selling 8,543 shares during the period. AbbVie accounts for about 0.8% of Sapient Capital LLC’s investment portfolio, making the stock its 23rd biggest holding. Sapient Capital LLC’s holdings in AbbVie were worth $49,110,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ABBV. Sovereign Financial Group Inc. increased its holdings in shares of AbbVie by 3.5% during the third quarter. Sovereign Financial Group Inc. now owns 3,685 shares of the company’s stock valued at $853,000 after purchasing an additional 124 shares during the period. Mayflower Financial Advisors LLC increased its stake in AbbVie by 21.8% during the 3rd quarter. Mayflower Financial Advisors LLC now owns 19,098 shares of the company’s stock valued at $4,422,000 after buying an additional 3,414 shares during the period. Rede Wealth LLC raised its position in shares of AbbVie by 388.2% during the 3rd quarter. Rede Wealth LLC now owns 8,528 shares of the company’s stock worth $1,975,000 after buying an additional 6,781 shares in the last quarter. BankPlus Trust Department lifted its stake in shares of AbbVie by 3.5% in the 3rd quarter. BankPlus Trust Department now owns 28,065 shares of the company’s stock worth $6,498,000 after acquiring an additional 952 shares during the period. Finally, Founders Grove Wealth Partners LLC boosted its holdings in shares of AbbVie by 3.6% in the third quarter. Founders Grove Wealth Partners LLC now owns 2,473 shares of the company’s stock valued at $573,000 after acquiring an additional 86 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Up 0.1%

Shares of AbbVie stock opened at $230.07 on Monday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market capitalization of $406.63 billion, a PE ratio of 174.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The stock’s fifty day moving average is $226.73 and its 200-day moving average is $212.72.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Analyst Ratings Changes

Several brokerages recently commented on ABBV. Citigroup dropped their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. UBS Group boosted their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Evercore ISI raised their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.